#Japan #Tokyo #Viatris #VR-205 #IgAN

Viatris Achieves Positive Outcomes in Phase 3 Clinical Trial of VR-205 for IgAN

Viatris Inc., a global leader in healthcare innovation, recently shared noteworthy findings from a Phase 3 clinical trial assessing the effectiveness and safety of its investigational drug VR-205 in Japanese adults suffering from primary immunoglobulin A nephropathy (IgAN). This disease is recognized for its potential to escalate into end-stage renal disease, necessitating effective treatment options.

The trial, which encompassed multiple centers and involved a significant cohort of Japanese patients, aimed to evaluate the impact of VR-205—a targeted-release formulation of budesonide (also known as Nefecon®). During the nine-month treatment phase, participants received 16 mg of VR-205 daily, followed by a three-month follow-up period that included a tapering of the dosage.

Key Findings of the Study

Among the trial's results, the most striking achievement was the primary endpoint, which demonstrated a remarkable 33.75 percent reduction in the geometric mean urine protein-to-creatinine ratio (UPCR) at the nine-month mark compared to baseline measurements. This statistic forms a strong basis for clinical significance, underlined by a p-value of less than 0.001, indicating robust statistical reliability. Additionally, patients exhibited substantial improvements in various secondary endpoints, including:

• - Enhanced estimated glomerular filtration rate (eGFR), indicating better kidney function.
• - Notable decreases in serum creatinine levels and urine albumin-to-creatinine ratio (UACR), further supporting the drug's favorable profile.
• - Improvements in microhematuria and sustained reduction in proteinuria, reinforcing the therapeutic benefits.

Encouragingly, none of the participants in the study advanced to require dialysis, kidney transplantation, or faced severe renal impairment by the trial's conclusion, showcasing the potential of VR-205 in altering the disease's progression.

VR-205's Safety and Efficacy Profile

The safety profile of VR-205 was commendable, with tolerability reflecting what has already been established in non-Japanese patient populations. Philippe Martin, the Chief Research and Development Officer at Viatris, conveyed optimism regarding these results, interpreting them as a pivotal step forward for treating patients with primary IgAN in Japan. He remarked, “This progress is a testament to our strategy of enhancing our portfolio in Japan, delivering effective therapies to address pressing healthcare needs.”

Yuko Asami, Head of Research and Development at Viatris Japan, also expressed enthusiasm about expanding treatment avenues for IgAN, a condition classified as an intractable disease in Japan, where the need for effective interventions is acute.

Regulatory Outlook and Future Steps

With these promising results, Viatris is preparing to file a New Drug Application in Japan by the close of 2026. This submission could pave the way for VR-205 to become the first targeted-release oral therapy specifically designed for IgAN in Japan, addressing an unmet medical need that has persisted due to the absence of curative options.

Currently, other regulatory pathways for VR-205 have been established, enabling its marketing as Tarpeyo® in the U.S. and Kinpeygo® in Europe, which increases the visibility and potential uptake of this innovative treatment.

IgA Nephropathy: A Public Health Concern

IgAN is recognized globally as the leading cause of primary glomerulonephritis, with Japan experiencing the highest incidence rates, ranging from 39 to 45 cases per million residents annually. This kidney disease dramatically impacts patient quality of life, with a significant portion of adults progressing to end-stage renal disease within ten years. The current landscape reveals that chronic glomerulonephritis, with IgAN as a primary cause, accounts for over 340,000 dialysis patients in Japan, exerting significant economic pressure on healthcare systems, approximated at JPY 1.5 trillion annually.

In summary, Viatris' Phase 3 trial results are a beacon of hope for thousands of patients in Japan grappling with IgAN. As the company moves forward with its development goals, it strives to ensure that effective therapies are within reach for those affected by this debilitating condition, marking a critical moment in the journey toward improved renal care.